Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" providers to prescribe its ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly, accusing the company of bribing medical providers to ...

Texas Attorney General Ken Paxton on Thursday announced a lawsuit alleging that Eli Lilly (NYSE:LLY) bribed his state's medical providers in a bid to persuade them to prescribe the company’s weight ...

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its ...

Its shares aren't exactly cheap at recent levels, though.

Eli Lilly said it believes the new data bolsters the case for Mounjaro to be prescribers’ first choice for patients with Type ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly, accusing the company of bribing medical providers to prescribe its lucrative medications. The lawsuit ...